Drucken

Sclerostin-LRP interaction screening system, LEADING LIGHT®

Lieferant: Enzo Life Sciences
Ratings: (keine Bewertung)

Gesamtbewertung: 0
Bewertung: 0.0 von 5

LEADING LIGHT®
ENZOENZ610030001EA 552.2 EUR
ENZOENZ610030001 ALEXENZ-61003-0001
Sclerostin-LRP interaction screening system, LEADING LIGHT®
Tests Enzymtests
Novel Cell-free Sclerostin/LRP Binding Assay Ideal for Primary Inhibitor Screens.

  • High sensitivity chemiluminescent readout (signal-to-noise ratio of ≥10)
  • Rapid protocol yields results in just 2,5 hours
  • No cell lines or transfection reagents required
  • Reproducible, high-throughput amenable assay (Z’-factor 0.871)
  • Amenable for high-throughput screening applications

The LEADING LIGHT® Sclerostin Screening System is a 1 x 96 well plate assay based on Sclerostin–LRP interaction. This system contains engineered LRP5-alkaline phosphatase (ALP) and human Sclerostin immobilized in a multi-well plate. LRP5-alkaline phosphatase binds to Sclerostin coated on the bottom of the well and is detected by the activity of alkaline phosphatase remaining after a washing step. This system can be used for drug screening to identify small molecule compounds, antibodies, DNA aptamers and peptides capable of modulating sclerostin-LRP interaction.

Bestellinformation: Contains Sclerostin microtiter plate, LRP5-ALP fusion protein concentrate, ALP concentrate (negative control), PBS solution, Blocking agent, wash buffer, acid green 25, ALP substrate reagent, plate sealer.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Mehr About VWR